Karma Biotechnologies Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Out of Business

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Out of Business

Karma Biotechnologies General Information

Description

Developer of drug therapeutics intended to elicit antigen-specific immune tolerance in vivo. The company leverages immunology and lipid nanoparticle engineering to develop off-the-shelf therapeutics to suppress the rogue immune responses that cause autoimmunity, allergies and food sensitivities, enabling pharmaceutical businesses to expand their allergy pipelines in competing markets.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 370 Amapola Avenue
  • Suite 101
  • Torrance, CA 90501
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 370 Amapola Avenue
  • Suite 101
  • Torrance, CA 90501
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Karma Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Out of Business 25-Jul-2025 Completed Out of Business
6. Secondary Transaction - Private Completed Generating Revenue
5. Seed Round 21-May-2023 Completed Generating Revenue
4. Seed Round 21-Oct-2021 Completed Generating Revenue
3. Seed Round 03-Sep-2019 Completed Generating Revenue
2. Seed Round 15-Aug-2019 $50K $100K Completed Generating Revenue
1. Seed Round 24-Apr-2017 $50K $50K Completed Startup
To view Karma Biotechnologies’s complete valuation and funding history, request access »

Karma Biotechnologies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-4
Seed-3
Seed-2 605,326 $0.000100 $0.01 $0.08 $0.08 $0.08 3.1%
Seed-1 3,926,187 $0.000100 $0.04 $0.51 $0.51 $0.51 20.14%
To view Karma Biotechnologies’s complete cap table history, request access »

Karma Biotechnologies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of drug therapeutics intended to elicit antigen-specific immune tolerance in vivo. The company leverages immun
Drug Discovery
Torrance, CA
3 As of 2024

South San Francisco, CA
 

Watertown, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Karma Biotechnologies Competitors (2)

One of Karma Biotechnologies’s 2 competitors is Parvus Therapeutics, a Venture Capital-Backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Parvus Therapeutics Venture Capital-Backed South San Francisco, CA
Selecta Biosciences Formerly VC-backed Watertown, MA
You’re viewing 2 of 2 competitors. Get the full list »

Karma Biotechnologies Patents

Karma Biotechnologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4463138-A1 Multi-vesicular lipid nanoparticle tolerogenic vaccines for induction of systemic immune tolerance in vivo Pending 14-Jan-2022
US-20250064740-A1 Multi-vesicular lipid nanoparticle tolerogenic vaccines for induction of systemic immune tolerance in vivo Pending 14-Jan-2022
WO-2023137227-A1 Multi-vesicular lipid nanoparticle tolerogenic vaccines for induction of systemic immune tolerance in vivo Inactive 14-Jan-2022
WO-2023137227-A9 Multi-vesicular lipid nanoparticle tolerogenic vaccines for induction of systemic immune tolerance in vivo Inactive 14-Jan-2022
EP-3784216-A1 Multi-vesicular liposomes for targeted delivery of drugs and biologics for tissue engineering Pending 27-Apr-2018 A61K31/337
To view Karma Biotechnologies’s complete patent history, request access »

Karma Biotechnologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Karma Biotechnologies FAQs

  • When was Karma Biotechnologies founded?

    Karma Biotechnologies was founded in 2017.

  • Where is Karma Biotechnologies headquartered?

    Karma Biotechnologies is headquartered in Torrance, CA.

  • What is the size of Karma Biotechnologies?

    Karma Biotechnologies has 3 total employees.

  • What industry is Karma Biotechnologies in?

    Karma Biotechnologies’s primary industry is Drug Discovery.

  • Is Karma Biotechnologies a private or public company?

    Karma Biotechnologies is a Private company.

  • What is Karma Biotechnologies’s current revenue?

    The current revenue for Karma Biotechnologies is .

  • How much funding has Karma Biotechnologies raised over time?

    Karma Biotechnologies has raised $4.98M.

  • Who are Karma Biotechnologies’s competitors?

    Parvus Therapeutics and Selecta Biosciences are competitors of Karma Biotechnologies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process